Heidi Móciková - Concepedia

Author

Heidi Móciková

Also Known As

H Mocikova, H Mociková, H Móciková, H. MOCIKOVA, H. Mocikova, H. Mocikovà, H. Mociková, H. Mócikova, H. Móciková, Heidi Mocikova

181

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Charles University University Hospital Kralovske Vinohrady University Hospital Brno University Hospital Hradec Králové University Hospital Olomouc

About

Heidi Móciková is an author at Charles University specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	531
2	Health Sciences	4	4	245
3	Public Health	1	1	12
4	Social Sciences	1	1	17
5	Cell Biology	1	1	14

Heidi Móciková

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, Journal of Clinical Oncology	2021	252
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network Chan Y. Cheah, Anupkumar George, Eva Giné, Annals of Oncology Prognostic FactorsNeuro-oncologyLymphoid NeoplasiaMantle Cell LymphomaPathology	2013	130
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R<sup>2</sup>‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma Umberto Vitolo, Thomas E. Witzig, Randy D. Gascoyne, Hematological Oncology Surgical OncologyCd20+ Abc-type DlbclImmunodeficienciesImmunologyPathology	2019	84
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels Kateřina Musilová, Ján Deván, Kateřina Amruz Černá, Blood	2018	72
Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma Heidi Móciková, Robert Pytlík, Jana Marková, Leukemia & lymphoma/Leukemia and lymphoma Cancer ManagementTransplantation MedicinePathologyPositron Emission TomographyOncology	2011	62
Role of [18F]-fluoro-2-deoxy-<scp>d</scp>-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone Jana Marková, Deniz Kahraman, Carsten Kobe, Leukemia & lymphoma/Leukemia and lymphoma Positron Emission TomographyLymphoid NeoplasiaOncologic ImagingGliomaInterim Pet	2011	57
Platelet activity and aspirin efficacy after off-pump compared with on-pump coronary artery bypass surgery: Results from the prospective randomized trial PRAGUE 11–Coronary Artery Bypass and REactivity of Thrombocytes (CABARET) František Bednář, Pavel Osmančík, Tomáš Vaněk, Journal of Thoracic and Cardiovascular Surgery	2008	46
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre, Blood	2022	44
Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study Heidi Móciková, Petra Obrtlíková, B Vacková, Annals of Oncology Positron Emission TomographyRetrospective StudyLymphoid NeoplasiaHodgkin LymphomaOncologic Imaging	2009	42

Page 1